HISUN(SH:600267) 智通财经网·2025-09-29 07:43Core Viewpoint - The company has received approval from the National Medical Products Administration for its Tacrolimus capsules, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval - The company has been granted a "Drug Supplement Application Approval Notice" for Tacrolimus capsules by the National Medical Products Administration [1] - Tacrolimus capsules are primarily used to prevent graft rejection after liver or kidney transplants [1] - The original drug Tacrolimus capsules were developed by Astellas Pharma Co. Limited [1] Group 2: Market Context - The main domestic manufacturers of Tacrolimus capsules include Zhejiang Haizheng Pharmaceutical Co., Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [1]